Pharmaceutical companies should prioritize rare diseases over widespread public health conditions

Population-level health initiatives, disease prevention, and health promotion.

Ethical issues in medicine and biomedical research: gene editing, reproductive technology, end-of-life care, organ markets, performance enhancement, and dual-use research.

Whistleblowing, proximity to power, government cover-ups, research funding conflicts, and race-corrected medical algorithms.